Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis.

Sci Rep · 2018 · PMC6133964 · PMID 30206422

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

ATROSAB-treated mice showed a highly significant reduction in disease severity in comparison to those treated with the control antibody, until 24 days after disease onset (Fig. 1C ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.